BioCentury | Mar 20, 2020
Finance

COVID stocks spike as market volatility continues

As the broader markets continue to tumble amidst the COVID-19 pandemic, several biotechs at the center of the race to develop countermasures have seen their valuations swing wildly since the crisis began to unfold in...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said EVP and CFO Shalini Sharp will step down by Sept. 2 to focus on serving as an adviser and board member for various biotech companies. Sharp will remain with the...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

A comparison of therapies that have shown promise, or failed to do so, in myasthenia gravis suggests targeting production of autoantibodies may be a less fruitful approach than blocking the effects of the autoantibodies or...
BC Extra | Jan 31, 2020
Financial News

Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts...
BC Extra | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

Apellis’ paroxysmal nocturnal hemoglobinuria candidate has beaten Soliris head-to-head on hemoglobin level improvement. Despite some ambiguity on how FDA will see the data, the company believes pegcetacoplan has a strong case for approval and could...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III miss for its lead mitochondria-targeted therapy in primary mitochondrial myopathy, just two months after Alexion obtained an option...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
Items per page:
1 - 10 of 1064
BioCentury | Mar 20, 2020
Finance

COVID stocks spike as market volatility continues

As the broader markets continue to tumble amidst the COVID-19 pandemic, several biotechs at the center of the race to develop countermasures have seen their valuations swing wildly since the crisis began to unfold in...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said EVP and CFO Shalini Sharp will step down by Sept. 2 to focus on serving as an adviser and board member for various biotech companies. Sharp will remain with the...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

A comparison of therapies that have shown promise, or failed to do so, in myasthenia gravis suggests targeting production of autoantibodies may be a less fruitful approach than blocking the effects of the autoantibodies or...
BC Extra | Jan 31, 2020
Financial News

Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts...
BC Extra | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

Apellis’ paroxysmal nocturnal hemoglobinuria candidate has beaten Soliris head-to-head on hemoglobin level improvement. Despite some ambiguity on how FDA will see the data, the company believes pegcetacoplan has a strong case for approval and could...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III miss for its lead mitochondria-targeted therapy in primary mitochondrial myopathy, just two months after Alexion obtained an option...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
Items per page:
1 - 10 of 1064